HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung ...

the trastuzumab-binding epitope (597–626) and the pertuzumab-binding epitope (266–296). All four peptide sequences inhibited tumor cell proliferation. Although all four sequences were ...

There are a few FDA-approved therapies, including trastuzumab and pertuzumab, that can treat this kind of cancer, but these ...

Enhertu belongs to a class of medicines called antibody-drug conjugates and is designed to target cancer cells while sparing the healthy ones. It combines a monoclonal antibody, trastuzumab ...

Approved across multiple indications, trastuzumab deruxtecan is indicated for various HER2-positive and HER2-low cancers, including breast, gastric, non-small cell lung cancer, and other solid tumors.

The EGFR family consists of four different members: EGFR; human epidermal growth factor receptor (HER) 2; HER3; and HER4. Upon ligand binding, these receptors can homodimerize or heterodimerize ...

Given the evolving role of trastuzumab deruxtecan (Enhertu) in the treatment of breast cancer, especially those who are HER2 positive, staying vigilant in looking for signs of adverse events (AEs) is ...